Unanswered questions hinder development of drops for macular disease

AMSTERDAM — Too many unanswered questions hinder development of eye drops for delivery to the back of the eye, one corporate executive told colleagues here. “I find it, at this point, very, very difficult to develop eye drops for the back of the eye in the face of all the questions to which we don’t have answers,“ Vice President and Head of GSK Ophthalmology Claudine Bruck said at the Ophthalmology Futures European Forum. For one, there is a need to identify which tissue – retinal or choroidal – to target. (Read more...)

Full Story →